Bacterial delivery of biologically active polypeptides

Details Bacterial delivery of biologically active polypeptides Bacterial delivery of biologically active polypeptides

2006-08-29

2011-11-29

Nickol, Gary B. (Department: 1645)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Bacteria or actinomycetales

Reexamination Certificate

active

08066987

ABSTRACT:
The present invention relates to methods for the delivery of biologically active polypeptides to a subject by colonizing non-pathogenic Gram negative bacteria. Also provided by this invention are methods of treating or preventing diseases by administering colonizing Gram negative bacteria that express one or more biologically active polypeptides. The colonizing non-pathogenic Gram negative bacteria may be administered in pharmaceutical formulations.

REFERENCES:
patent: 6605286 (2003-08-01), Steidler et al.
patent: 6746671 (2004-06-01), Steidler et al.
patent: 6866847 (2005-03-01), Kelly-Aehle
patent: 2004/0170639 (2004-09-01), Kelly-Aehle
patent: 0413378 (1990-07-01), None
patent: 0413378 (1995-01-01), None
patent: WO00/04919 (2000-02-01), None
patent: WO01/19974 (2001-03-01), None
Zhu, Delivery of heterologous protein antigens via hemolysin or autotransporter systems by an attenuated ler mutant of rabbit enteropathogenicEscherichia coli, Center for Vaccine Development, University of Maryland School of Medicine, 685 West Baltimore Street, Baltimore, MD 21201, USA, pp. 1-11, 2005.
Castagliuolo, EngineeredE. colidelivers therapeutic genes to the colonic mucosa, Department of Histology, Microbiology and Medical Biotechnologies, University of Padua, Padua, Italy, Gene therapy, 12, pp. 1070-1078, 2005.
Lui, Expression of Rumen Microbial Fibrolytic Enzyme Genes in ProbioticLactobacillus reuteri, Applied and Environmental Microbiology, Nov. 2005, p. 6769-6775, vol. 71, No. 11.
Huyghebaert, et al, Development of an enteric-coated formulation containing freeze-dried, viable recombinantLactococcus lactisfor the ileal mucosal delivery of human interleukin-10, European Journal of Biopharmaceuticals, Aug. 2005;60(3):349-359.
Roland, Recent advances in the development of live, attenuated bacterial vectors, Current Opinion in molecular therapeutics, (1):62-72, Jul. 1, 2005.
Ingham, A versatile system for the expression of nonmodified bacteriocins inEscherichia coli, Journal of Applied Microbiology, 2005;98(3):676-683.
Mergulha, Recombinant protein secretion inEscherichia coli, Biotechnology Advances, vol. 23, Issue 3, May 2005, pp. 177-202.
Prakash, Artificial Cell Therapy: New Strategies for the Therapeutic Delivery of Live Bacteria, Biomed Biotechnol. 2005; 2005(1): 44-56.
Palacios, Characterization of an acid phosphatase fromLactobacillus pentosus: regulation and biochemical properties, Journal of Applied Microbiology, vol. 98, No. 1, Jan. 2005 , pp. 229-237(9).
Choi, Secretory and extracellular production of recombinant proteins usingEscherichia coli, Applied Microbiology and Biotechnology, vol. 64, No. 5, Jun. 2004 , pp. 625-635(11).
Kimoto, NewLactococcusstrain with immunomodulatory activity: enhancement of Th1-type immune response, Microbiology Immunology, 2004;48(2):75-82.
Boman, Antibacterial peptides: basic facts and emerging concepts, Journal of Medicine, Sep. 2003;254(3):197-215.
Steidler, Biological containment of genetically modifiedLactococcus lactisfor intestinal delivery of human interleukin 10, Nature Biotechnology, Jul. 2003;21(7):785-9. Epub Jun. 15, 2003.
Bermudez, Intranasal Immunization with RecombinantLactococcus lactisSecreting Murine Interleukin-12 Enhances Antigen-Specific Th1 Cytokine Production, Infect Immun. Apr. 2003; 71(4): 1887-1896.
Ingham, The bacteriocin piscicolin 126 retains antilisterial activity in vivo, Journal of Antimicrobial Chemotherapy vol. 51, No. 6, pp. 1365-1371, 2003.
Vohra, Phytases: Microbial sources, production, purification, and potential biotechnological applications, Critical Reviews in Biotechnology, pp. 29-60, Mar. 1, 2003.
Garmory, The use of live attenuated bacteria as a delivery system for heterologous antigens, Journal of Drug Targeting, 2003;11(8-10):471-479.
Cullen, Construction and evaluation of a plasmid vector for the expression of recombinant lipoproteins inEscherichia coli, Plasmid 49, Jan. 2003;49(1):18-29.
Steidler, in situ delivery of cytokines by genetically engineeredLactococcus lactis, vol. 82, Nos. 1-4, Aug. 2002, pp. 323-331(9).
King, Tumor-Targeted Salmonella Expressing Cytosine Deaminase as an Anticancer Agent, Human Gene Therapy. Jul. 1, 2002, 13(10): 1225-1233.
Medina, Use of live bacterial vaccine vectors for antigen delivery: potential and limitations, Vaccine, vol. 19, Feb. 8, 2001, pp. 1573-1580.
Cho, Expression ofClostridium thermocellumendoglucanase gene inLactobacillus gasseriandLactobacillus johnsoniiand characterization of the genetically modified probioticLactobacilli, Current microbiology, vol. 40, pp. 257-263, 2000.
Ennahar, Class IIa bacteriocins : biosynthesis, structure and activity, FEMS microbiology reviews, 2000, vol. 24, pp. 85-106.
Kalhusdal, Necrotic enteritis challenge models with broiler chickens raised on litter: evaluation of preconditions,Clostridium perfringensstrains and outcome variables, Femms Immunology and Medical Microbiology 24, (1999) 337-343.
Craven, Cecal carriage ofClostridium perfringensin broiler chickens given Mucosal Starter Culture, Avian Diseases, Jul.-Sep. 1999;43(3):484-90.
Saltzman, Patterns of hepatic and splenic colonization by an attenuated strain ofSalmonella typhimuriumcontaining the gene for human interleukin-2: a novel anti-tumor agent, Cancer Biotherapy & Radiopharmaceuticals, Feb. 1997;12(1):37-45.
Bhugaloo-Vial, Purification and amino acid sequences of piscicocins V1a and V1b, two class IIa bacteriocins secreted byCarnobacterium piscicolaV1 that display significantly different levels of specific inhibitory activity, Appl. Environ. Microbiol., Dec. 1996, 4410-4416, vol. 62, No. 12.
Jack, Bacteriocins of gram-positive bacteria, Microbiol Rev. Jun. 1995; 59(2): 171-200.
Boman, Peptide antibiotics and their role in innate immunity, Annual Review of Immunology, 1995;13:61-92.
Nahashon, Phytase activity, phosphorus and calcium retention, and performance of single comb White Leghorn layers fed diets containing two levels of available phosphorus and supplemented with direct-fed microbials, Poltry Science, Oct. 1994;73(10):1552-62.
Devriese, in vitro susceptibility ofClostridium perfringensisolated from farm animals to growth-enhancing antibiotics, Journal of Applied Bacteriology, Jul. 1993;75(1):55-7.
Tacket, Clinical acceptability and immunogenicity of CVD 908Salmonella typhivaccine strain, Vaccine, vol. 10, 1992;10(7):443-6.
Tschirdewahn, The presence of enterotoxigenicClostridium perfringensstrains in faeces of various animals, International Journal of Food Microbiology, Nov. 1991;14(2):175-8.
Gabay, Antibiotic proteins of human polymorphonuclear leukocytes, Proc Natl Acad Sci U S A. Jul. 1989; 86(14): 5610-5614.
Soravia, Antimicrobial properties of peptides from Xenopus granular gland secretions, Federation of European Biochemical Societies Feb. 15, 1988;228(2):337-340.
Cowan, Experimentally Induced Necrotic Enteritis in Chickens, Avian Diseases 31,:904-906, 1987.
Kondo, In vitro lecithinase activity and sensitivity to 22 antimicrobial agents ofClostridium perfringensisolated from necrotic enteritis of broiler chickens, Research in Veterinary Science, Nov. 1988;45(3):337-340.
Tagg, Bacteriocins of gram-positive bacteria, American Society for Microbiology, Sep. 1976, 9p. 722-756.
Agars, isolation ofshigella, The American Journal of clinical pathology, 1965, vol. 44, No. 4.
Hektoen, New culture medium for the isolation ofBacillus typhosusfrom stools, the journal of infectious diseases, vol. 18, 1916.
Alfred MacConkey, Lactose-ferminting bacteria in faeces, The journal of hygiene, vol. 5, No. 3, pp. 333-379, Jul. 1905.
Curtiss III; et al., “Nonrecombinant and recombinant avirulent Salmonella vaccines for poultry”, Veterinary Immunology and Immunopathology (1996), 54:365-372.
Kulkarni; et al., “Oral immunization of broiler chickens against necrotic enteritis with an attenuated Salmonella vaccine vector expressing Clostridium perfringens antigens”, Vaccine (2008), 26:4194-4203.
“Supplementary European Search Report”, European Patent Office, Apr. 24, 2009, 06774884.8-2403 / 1934349.
Weiss; et al., “Bacteria-Medi

Affiliated with

Also associated with

Rating

Bacterial delivery of biologically active polypeptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Bacterial delivery of biologically active polypeptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bacterial delivery of biologically active polypeptides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4252849